MBF Therapeutics’ Founder and CEO Tom Tillett to speak at ASPIRE Philadelphia Dealmakers Conference

June 05, 2019 – Philadelphia, PA – Tom Tillett, founder and CEO of Ambler, Pa.-based MBF Therapeutics (MBFT), will speak at the ASPIRE Middle-Market Dealmakers Conference in Philadelphia on Wednesday, June 12.

ASPIRE connects entrepreneurs, investors and dealmakers for a day of dynamic content and networking in top business markets across the U.S. The event takes place from 7:15 a.m. to 5 p.m. at Philadelphia 201 Hotel.

Tillett is a featured speaker on “Building Strong Capital Stacks: How to Raise Capital to Fuel Your Organization’s Growth.” The panel features business owners and experts who challenge the conventional norms to seek out and secure capital to finance accelerated growth.

MBFT’s lead product is MBFT-201, a canine melanoma vaccine for dogs with Stage II/III resectable disease. The company has completed two Pilot studies that demonstrate the safety of the product and a strong immune response to key antigens in 100 percent of the dogs treated. MBFT has recently begun development of a vaccine for African Swine Fever (ASF), a devastating disease affecting the global pork industry.

Tillett joins a group of local peers, including Joseph M. Finley, regional president, Eastern Pennsylvania, TriState Capital Bank; Daniel J. Hayes, director, outsourcing, Life Science, CLA; and Taylor Rooke, vice president, Rooke Fiduciary Management.

“I am delighted to present and share my experience with this audience of investors, dealmakers and fellow entrepreneurs,” Tillet said.

Entreprenuers and investors who are interested in hearing Tillett speak can register to attend ASPIRE by visiting www.aspiredealmakers.com/philadelphia/register/ and entering promo code: Tillett100 to receive $100 off their ticket.